UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~March 2026, 2026

ROCKWELL MEDICAL, INC.

(Exact name of registrant as specified in its charter)


Delaware	000-23661	38-3317208
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

30142 S. Wixom Road, Wixom, Michigan 48393

(Address of principal executive offices, including zip code)

(248) 960-9009

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each exchange on which registered

Common Stock, par value $0.0001

RMTI

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2 7.0201 ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

On ~~January~~March 2026, 2026, Rockwell Medical, Inc. ~~(the~~made ~~“Company”)~~available ~~issued~~an aupdated ~~press~~corporate ~~release~~presentation. ~~announcing~~A ~~preliminary,~~copy ~~unaudited~~of ~~financial results for~~ the ~~quarter~~corporate ~~and~~presentation ~~year ended December 31, 2025. The press release~~ is furnished herewith as Exhibit 99.1 toand ~~this~~incorporated ~~Current~~by ~~Report~~reference ~~on Form 8-K~~herein.

~~The~~In ~~preliminary,~~accordance ~~unaudited~~with ~~financial~~General ~~information~~Instruction ~~contained~~B.2 inof Form 8-K, the ~~press~~information ~~release~~in isthis ~~based~~Current Report on ~~management’s~~Form ~~initial~~8-K, ~~analysis~~including Exhibit 99.1, shall not be deemed to be “filed” for ~~the~~purposes ~~three~~of ~~months~~Section ~~and~~18 ~~twelve~~of ~~months~~the ~~ended~~Securities ~~December~~Exchange 31Act of 1934, ~~2025~~as amended (the “Exchange Act”), ~~and~~or isotherwise subject to ~~completion~~the liabilities of ~~the~~that ~~Company’s~~section, ~~quarter-end~~ and ~~year-end~~shall ~~financial~~not ~~closing~~be ~~procedures,~~incorporated ~~internal~~by ~~review,~~reference ~~and~~into ~~audit~~any byregistration ~~the~~statement ~~Company’s~~or ~~independent~~other ~~registered~~document ~~public~~filed ~~accounting~~under ~~firm. As~~the aSecurities ~~result~~Act of 1933, as amended, or the ~~actual~~Exchange ~~results~~Act, ~~may~~except ~~differ~~as ~~from~~shall ~~the~~be ~~preliminary~~expressly ~~results~~set ~~disclosed~~forth by specific reference in such filing.

As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Certain statements contained in the press release filed herewith may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are committed to,” “are on track,” “are resolute in our vision,” "work to," "drive towards," “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. Such statements include statements relating to the Company’s preliminary unaudited financial results for the three months and twelve months ended December 31, 2025 and other preliminary estimates or future financial condition and operating results, and its focus on increasing revenue, delivering sustainable profitability, reducing costs, and further diversifying its portfolio of products to deliver continued growth and create lasting value for shareholders. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in the Company’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. The Company expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits The following exhibit is being furnished herewith:

EXHIBIT INDEX

Exhibit No.						Description
99.1						~~Press~~Rockwell ~~release~~Medical, Inc. Corporate Presentation, dated ~~January~~March 2026, 2026
104						Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROCKWELL MEDICAL, INC.
Date: January 20, 2026	By:	/s/ Mark Strobeck
Date: March 26, 2026	By:	/s/ Mark Strobeck
		Mark Strobeck
		Chief Executive Officer

Filing Compare · ROCKWELL MEDICAL, INC.